Producing a monoclonal antibody from a DNA sequence is a major scientific challenge—and the process becomes harder still when the antibody must be manufactured at scale. By constructing a robust production workflow, focusing on the three main pillars described below, researchers can save time, reduce costs, and ensure that critical project milestones are achieved, however much antibody is required.
A typical workflow for producing antibodies in a mammalian cell line involves a series of steps, beginning with identification of the antibody sequence. This could come from an existing monoclonal, a phage display antibody library, or another sequencing method. Next, the antibody gene must be synthesized and inserted into a vector, which is then used to transfect a mammalian cell line. After screening for properties including specificity and affinity, desirable antibodies are purified and subjected to rigorous quality control measures, such as assessment of purity and integrity by SDS-PAGE under both reducing and non-reducing conditions.
Figure 1. In vitro antibody production workflow
When developing a cell line for antibody production, it is important to choose the right vector. While a strong promoter, such as the cytomegalovirus (CMV) promoter, is a given, the selection marker is equally key. Drug-selection markers and fluorescent protein markers have long been used to identify positively transfected cells. However, markers based on the Glutamine Synthetase (GS) system are increasingly popular, since they ensure that only the most stable, high-expressing cells are able to grow, leading to a very clean monoclonal population.
The choice of host cell is also vital. Chinese Hamster Ovary (CHO) cells are commonly used for antibody production because they can perform human-like post-translational modifications. This ensures that the antibody is functional and helps to prevent it from being recognized as foreign by the human immune system—a crucial consideration for therapeutic applications. Various types of CHO cells are available, including the ExpiCHO-S line, which is optimized for high-density suspension culture in bioreactors and can thus support scalable production.
Another factor to consider is how the antibody candidates will be screened in order to isolate a “champion” clone for the Master Cell Bank (MCB). Where possible, it is recommended to use an automated, high-throughput platform for antibody screening, and to apply a funnel approach (e.g., testing of mini-pools) to cull the herd before taking the top candidates into shake flask studies. At the end of the screening process, antibody monoclonality should be confirmed by limiting dilution.
Once the champion clone has been identified and banked, the next step is to squeeze as much performance out of it as possible through upstream process optimization. For the antibody to be commercially viable, titers should be in the ultra-high range (>1.5 g/L) to help lower the final cost.
An effective approach is to perform methodical testing of different media and nutrient feeds in shake flasks to establish a fed-batch strategy that consistently delivers the best yields. Arguably the single most powerful lever, however, is to introduce a programmed temperature shift. Ramping the culture temperature down from 37°C to around 34°C in the middle of a run will gently bring cell division to a halt, while freeing up metabolic energy for antibody production.
With a high-yield cell line in hand and a fully optimized upstream process developed, the final step is to prove that antibody production is robust and predictable when taken to a larger scale. The aim here is not to continue chasing record titers, but to demonstrate that performance can be precisely and consistently replicated in a bioreactor. Single-use systems are invaluable at this stage since they eliminate the need for cleaning steps, which are required with stainless-steel tanks, thus removing the risk of cross-contamination. Success is defined by near-identical performance curves between the shake flask and the bioreactor.
The journey from a DNA sequence to a scalable bioreactor process for antibody production requires significant time and effort. To address this challenge, Creative Biolabs has developed a high-throughput antibody production service that can deliver hundreds of purified recombinant antibodies in as little as two weeks for the discovery phase. Furthermore, for lead candidates, its end-to-end CDMO solutions can seamlessly guide projects through process development and into scalable manufacturing. This full-spectrum support allows research teams to focus on what matters most—downstream analysis and innovation. To find out more, visit https://www.creativebiolabs.net/one-stop-cdmo-solutions.htm